Xuzhou, China

Liang Chen

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Nhwa Pharma. Corporation. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Liang Chen. Retrieved from https://idiyas.com/inventor/liang-chen-w2mrq95t

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Liang Chen: Pharmaceutical Process Inventor

Introduction

Liang Chen is an inventor based in Xuzhou, China, associated with Nhwa Pharma Corporation. His patent work concerns a manufacturing process for agomelatine and an intermediate used in its production. He is credited with 1 patent.

Latest Patents

Chen’s listed patent, “Process for the Manufacture of Agomelatine and Its Intermediate,” describes a route to agomelatine and the intermediate N-[2-(7-methoxy-1-naphthyl)ethyl]phthalimide. The process reacts 7-methoxy-1-naphthyl ethanol with benzenesulfonyl chloride to form 7-methoxy-1-naphthylethyl benzenesulfonate. That compound is then reacted with potassium phthalimide to produce the phthalimide intermediate, which undergoes alkaline hydrolysis and acetylation to obtain agomelatine.

Career Highlights

Chen’s documented patent contribution focuses on a defined sequence of chemical reactions for producing agomelatine and its intermediate. The available information associates his work with Nhwa Pharma Corporation and does not provide further details about his role or career history.

Collaborations

Yanqin Ma and Xiangping Yang are identified as Chen’s coworkers. The supplied information does not specify their roles in the patent or the manufacturing process.

Conclusion

Liang Chen’s listed invention addresses the manufacture of agomelatine through a process that produces a key intermediate and converts it into the final compound.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…